In CD19-targeting CAR-T cell therapy for B cell acute lymphocytic leukemia (B-ALL), persistent single-target immunotherapy may induce selection pressure that triggers CD19 gene mutations, leading to reduced or absent surface expression [14,15]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.